What’s in AstraZeneca plc (ADR) After Today’s Bullish Options Activity?

 What's in AstraZeneca plc (ADR) After Today's Bullish Options Activity?

In today’s session AstraZeneca plc (ADR) (AZN) registered an unusually high (327) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the April, 2017 call, expecting serious AZN increase. With 327 contracts traded and 46154 open interest for the Apr, 17 contract, it seems this is a quite bullish bet. The option with symbol: AZN170421C00030000 closed last at: $0.7 or 30% down. The stock decreased 0.23% or $0.06 on November 23, hitting $26.37. About 13.54M shares traded hands or 98.53% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 12.39% since April 22, 2016 and is downtrending. It has underperformed by 17.80% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 earnings per share, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.39B for 11.57 P/E if the $0.57 EPS becomes a reality. After $1.32 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Monday, November 2 by Nordea. The stock has “Buy” rating given by Bryan Garnier & Cie on Friday, September 18. The stock has “Hold” rating given by Jefferies on Tuesday, March 15. As per Friday, July 31, the company rating was upgraded by S&P Research. Piperjaffray initiated AstraZeneca plc (ADR) (NYSE:AZN) on Friday, September 23 with “Overweight” rating. As per Monday, February 8, the company rating was downgraded by HBSC. The firm earned “Underperform” rating on Tuesday, October 20 by Credit Suisse. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Neutral” rating given on Wednesday, September 14 by BNP Paribas. The company was upgraded on Tuesday, January 19 by Barclays Capital. The rating was upgraded by Swedbank on Friday, July 31 to “Buy”.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $64.09 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 27.07 P/E ratio. The Firm has its activities in over 100 countries.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

More news for AstraZeneca plc (ADR) (NYSE:AZN) were recently published by: Investorplace.com, which released: “5 Stocks With Prime Operating Margin — NAII CYS BYFC IESC AZN” on August 29, 2016. Businessfinancenews.com‘s article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” and published on August 01, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment